Exploiting genomics in the search for new drugs
AssigneeAffymetrix, Inc.
InventorsDavid J. Lockhart, Lisa Wodicka, Ming Hsiu Ho
Life of this patent
Estimating the term…
Abstract
The cellular effects of potentially therapeutic compounds are characterized in mammalian cells and yeast. In the latter case the effects can be characterized on a genome-wide scale by monitoring changes in messenger RNA levels in treated cells with high-density oligonucleotide probe arrays.
Claims79
A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is down-regulated in response to both compound 52 and flavopiridol.
A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated in response to both compound 52 and flavopiridol.
A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is down-regulated in response to compound 52 but not to flavopiridol.
A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated in response to compound 52 but not to flavopiridol.
A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is down-regulated in response to flavopiridol but not to compound 52.
A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated in response to flavopiridol but not to compound 52.
A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is down-regulated in cdc28-4 mutants.
A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is down-regulated or up-regulated in response to both compound 52 and flavopiridol.
A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated or down-regulated in cdc28-4 mutants.
A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated in cdc28-4 mutants.
The set of any of the preceding claims wherein the genes are yeast genes.
The set of any of the preceding claims wherein the genes are human genes.
The set of any of the preceding claims wherein the probes are immobilized on a solid support.
The set of any of the preceding claims wherein the probes are immobilized on an array.
The set of any of the preceding claims wherein up-regulation or down-regulation is determined by a difference of at least three-fold from a control.
The set of any of the preceding claims which comprises at least 3, probes.
The set of any of the preceding claims which comprises at least 5 probes.
The set of any of the preceding claims which comprises at least 7 probes.
The set of any of the preceding claims which comprises at least 9 probes.
The set of any of the preceding claims which comprises at least 11 probes.
The set of any of the preceding claims which comprises at least 20 probes.
The set of any of the preceding claims which comprises at least 30 probes.
The set of any of the preceding claims which consists of less than 100 probes.
The set of any of the preceding claims which consists of less than 1000 probes.
The set of any of the preceding claims which comprises less than 10000 probes.
A method of comparing the specificity of drugs, comprising:
- contacting a first drug with a first population of cells and a second drug with a second population of said cells;
- preparing a transcription indicator from each of the first and the second populations of cells, wherein a transcription indicator is selected from the group consisting of cellular RNA, cellular mRNA, cRNA and cDNA;
- preparing a transcription indicator from a third population of said cells which is not contacted with a drug;
- hybridizing the transcription indicators to oligonucleotide arrays to form a pattern of hybridization for each of said populations of cells;
- comparing each of the first and the second populations' patterns of hybridization to the third population's pattern of hybridization to identify changes induced by the first and the second drugs;
- comparing changes induced by the first and second drugs, wherein a drug which effects more changes is less specific than a drug which effects fewer changes.
A method of comparing the effects of a drug to the effects of a mutation, comprising:
- contacting a drug with a first population of cells;
- preparing a transcription indicator from the first population of cells, wherein a transcription indicator is selected from the group consisting of cellular RNA, cellular mRNA, cRNA and cDNA;
- preparing a transcription indicator from a second population of cells which population is not contacted with a drug, wherein the second population of cells carry a mutation in a gene of interest relative to the first population of cells;
- preparing a transcription indicator from a third population of cells which is not contacted with a drug and which does not carry the mutation;
- hybridizing the transcription indicators to oligonucleotide arrays to form a pattern of hybridization for each of said populations of cells;
- comparing each of the first and the second populations' patterns of hybridization to the third population's pattern of hybridization to identify changes caused by the drug and the mutation;
- comparing the changes caused by the drug to those caused by the mutation;
- wherein a drug and a mutation which affect hybridization to one or more common oligonucleotides identifies the gene of interest as a candidate target of the drug;
- wherein a drug which affects hybridization to both common oligonucleotides and unique oligonucleotides identifies the drug as affecting targets other than the gene.
A method of comparing the specificity of drugs, comprising:
- comparing changes in expression induced by a first drug to those induced by a second drug, wherein a drug which effects more changes is less specific than a drug which effects fewer changes, wherein the changes are determined the process of:
- contacting the first drug with a first population of cells and the second drug with a second population of said cells;
- preparing a transcription indicator from each of the first and the second populations of cells, wherein a transcription indicator is selected from the group consisting of cellular RNA, cellular mRNA, cRNA and cDNA;
- preparing a transcription indicator from a third population of said cells which is not contacted with a drug;
- hybridizing the transcription indicators to oligonucleotide arrays to form a pattern of hybridization for each of said populations of cells;
- and
- comparing a first and a second populations' patterns of hybridization to a third population's pattern of hybridization to identify changes induced by the first and the second drugs.
A method of comparing the effects of a drug to the effects of a mutation, comprising:
- comparing changes in expression caused by a drug to those caused by a mutation, wherein the changes in expression are determined by the process of:
- contacting the drug with a first population of cells;
- preparing a transcription indicator from the first population of cells, wherein a transcription indicator is selected from the group consisting of cellular RNA, cellular mRNA, cRNA and cDNA;
- preparing a transcription indicator from a second population of cells which population is not contacted with a drug, wherein the second population of cells carry the mutation in a gene of interest relative to the first population of cells;
- preparing a transcription indicator from a third population of cells which is not contacted with a drug and which does not carry the mutation;
- hybridizing the transcription indicators to oligonucleotide arrays to form a pattern of hybridization for each of said populations of cells;
- comparing each of the first and the second populations' patterns of hybridization to the third population's pattern of hybridization to identify changes caused by the drug and the mutation;
- wherein a drug and a mutation which affect hybridization to one or more common oligonucleotides identifies the gene of interest as a candidate target of the drug;
- wherein a drug which affects hybridization to both common oligonucleotides and unique oligonucleotides identifies the drug as affecting targets other than the gene.
Dependencies are inferred from the claim text.